Metachronous basal cell carcinoma and primary plasmacytic leukemia associated with dermatomyositis

Dermatomiyozit sıklıkla kanserle ilişkilendirilir. Öte yandan, aynı kişide art arda iki malignitenin gelişmesi nadirdir. Bu yazıda, deri lezyonları, kas zayıflığı, artmış kas enzimleri, elektromiyografi ve kas biyopsisine dayanılarak dermatomiyozit tanısı konulmuş 71 yaşında bir kadın hasta sunuldu. İki yıl sonra, hastada sol nazolabial kanalda ülser gelişti. Doku biyopsisi ile bazal hücreli karsinomun kesinleşmesinin ardından rezeksiyon uygulandı. Rezeksiyondan iki yıl sonra, hastanın kemik iliği biyopsisinde serum M protein, üriner l hafif zincir ve neoplastik plazma hücre infiltrasyonu değerlendirildi. Bulgular plazmasitik lösemi ile uyumluydu. Dermatomiyozit hastalarında karsinojenik yatkınlık nedeniyle birden fazla tümör gelişebilir. Bu nedenle, hekimler dermatomiyozit hastalarını ilk tümör gelişiminden sonra takip etmeye devam etmelidir, çünkü bu hastalarda başka malignitelerin gelişme olasılığı vardır.

Dermatomiyozit ile ilişkili metakron basal hücreli karsinom ve primer plazmasitik lösemi

Dermatomyositis is associated with cancer frequently. However, successive occurrence of two malignancies in one person is rare. In this article, we present a 71-year-old female patient who was diagnosed as dermatomyositis based on skin lesions, muscle weakness, elevated muscle enzymes, electromyography, and muscle biopsy. Two years later, the patient had an ulcer on the left nasolabial groove. A resection was performed after basal cell carcinoma was confirmed by tissue biopsy. Two years after resection, serum M protein, urinary l light chain, and neoplastic plasma cells infiltration in bone marrow biopsy of the patient were evaluated. Findings were compatible with the plasmacytic leukemia. Dermatomyositis patients may suffer from multiple tumors due to carcinogenic susceptibility. Therefore, physicians should continue to monitor dermatomyositis patients after the occurrence of the first tumor since they still have the possibility of developing another malignancy.

Kaynakça

Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide populationbased study. Br J Dermatol 2009;161:854-60.

Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977;56:255-86.

Callen JP. Dermatomyositis and multiple malignancies in a patient treated with methotrexate. J Surg Oncol 1983;24:113-6.

Voravud N, Dimopoulos M, Hortobagyi G, Ross M, Theriault R. Breast cancer and second primary ovarian cancer in dermatomyositis. Gynecol Oncol 1991;43:286-90.

Murgic J, Prpic M, Kirac I, Camino-Varela AM, Bolanca A, Kusic Z. Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer. Coll Antropol 2012;36:325-9.

Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.

Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.

Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.

Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995;6:9-13.

Lee SW, Jung SY, Park MC, Park YB, Lee SK. Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J 2006;47:519-23.

Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001;144:825-31.

Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9.

Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007;46:25-8.

Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682-9.

Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep 2006;8:196-203.

Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009;34:561-5.

Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990;33:1361-70.

Kaynak Göster